Is it Good Time to Bail on Applied Genetic Technologies Corporation [AGTC]? Let’s Look at the Charts

In a recent bid Applied Genetic Technologies Corporation [AGTC] faced a contemporary bid of $5.15 yielding a 12.62% incline where 0.86 million shares have exchanged hands over the last week. AGTC amount got a boost by 6.85% or $0.33 versus $4.82 at the end of the prior session. This change led market cap to move at 123.63M, putting the price 124.89% below the 52-week high and -50.58% above the 52-week low. The company’s stock has a normal trading capacity of 0.86 million shares while the relative volume is 7.94.

On 16, November 2020, AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020. According to news published on Yahoo Finance, Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended September 30, 2020. The Company is also providing an update on its ongoing clinical trials in patients with X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM).

Analyst Birdseye View:

The most recent analyst activity for Applied Genetic Technologies Corporation [NASDAQ:AGTC] stock was on June 23, 2020, when it was Initiated with an Overweight rating from Cantor Fitzgerald, which also raised its 12-month price target on the stock to $14. On January 28, 2020, ROTH Capital Initiated a Buy rating. On January 27, 2020, ROTH Capital Initiated a Buy rating. On September 27, 2019, BMO Capital Markets Upgrade an Outperform rating and increased its price target to $9. On September 27, 2019, H.C. Wainwright Reiterated a Buy rating and boosted its amount target on this stock to $18. On September 06, 2019, Janney Initiated a Buy rating and boosted its target amount on this stock to $13. Stifel elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.29 and a peak of $10.42. Right now, the middling Wall Street analyst 12-month amount mark is $14.00. At the most recent market close, shares of Applied Genetic Technologies Corporation [NASDAQ:AGTC] were valued at $5.15.

FUNDAMENTAL ANALYSIS

This publicly-traded organization’s revenue is $29,554 per employee, while its income is -$552,916 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -47.67, -61.30, -57.03 and -56.13 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 17.33 and the whole liability to whole assets at 14.84. It shows enduring liability to the whole principal at 16.05 and enduring liability to assets at 0.14 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 4.48 points at 1st support level, the second support level is making up to 4.15. But as of 1st resistance point, this stock is sitting at 5.06 and at 5.31 for 2nd resistance point.

Applied Genetic Technologies Corporation [AGTC] reported its earnings at -$0.6 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.53/share signifying the difference of -0.07 and -13.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.56 calling estimates for -$0.48/share with the difference of -0.08 depicting the surprise of -16.70%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Applied Genetic Technologies Corporation [NASDAQ:AGTC] is 5.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 6.21. Now if looking for a valuation of this stock’s amount to sales ratio it’s 47.66 and it’s amount to book ratio is 2.01.

Insider Stories

The most recent insider trade was by Krol Patrick Johan Hendrik, 10% Owner, and it was the sale of 81162.0 shares on Dec 26.